Barbara Buldini

Padova, 35128, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 90 publications

Comparative Study of Single-Cell and Bulk RNA Sequencing Data from Metastatic Bone Marrow Neuroblastoma Samples.

Comparative Study of Single-Cell and Bulk RNA Sequencing Data from Metastatic Bone Marrow Neuroblastoma Samples.

Journal: Cells

Published: May 12, 2026

Venetoclax and azacytidine in childhood primary advanced myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia and therapy-related myeloid neoplasms.

Venetoclax and azacytidine in childhood primary advanced myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia and therapy-related myeloid neoplasms.

Journal: Haematologica

Published: February 25, 2026

Plasticity under pressure: biology and detection of lineage switch in acute leukemia.

Plasticity under pressure: biology and detection of lineage switch in acute leukemia.

Journal: Leukemia

Published: February 25, 2026

Measurable Residual Disease-Dependent Unfavorable Outcomes in Pediatric PAX5-Rearranged B-Acute Lymphoblastic Leukemia.

Measurable Residual Disease-Dependent Unfavorable Outcomes in Pediatric PAX5-Rearranged B-Acute Lymphoblastic Leukemia.

Journal: Blood

Published: February 13, 2026

Improved outcomes of the refined risk-stratification and risk-adapted therapy in children with acute myeloid leukemia: final results of the AIEOP AML 2013.

Improved outcomes of the refined risk-stratification and risk-adapted therapy in children with acute myeloid leukemia: final results of the AIEOP AML 2013.

Journal: Journal of hematology & oncology

Published: February 08, 2026

Reducing Daunorubicin in Induction Therapy in Children With B-Lineage ALL With Favorable Prognosis: Results of Phase III Trial AIEOP-BFM ALL 2009.

Reducing Daunorubicin in Induction Therapy in Children With B-Lineage ALL With Favorable Prognosis: Results of Phase III Trial AIEOP-BFM ALL 2009.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: November 10, 2025

American Society of Hematology 2026 guidelines for management of relapsed/refractory acute lymphoblastic leukemia in adolescents and young adults.

American Society of Hematology 2026 guidelines for management of relapsed/refractory acute lymphoblastic leukemia in adolescents and young adults.

Journal: Blood advances

Published: October 06, 2025

ASH 2026 Guidelines for Management of Relapsed/Refractory Disease in Adolescents and Young Adults with ALL.

ASH 2026 Guidelines for Management of Relapsed/Refractory Disease in Adolescents and Young Adults with ALL.

Journal: Blood advances

Published: October 06, 2025

Advancing precision therapy in pediatric acute myeloid leukemia through PDX models and mitochondrial targeting.

Advancing precision therapy in pediatric acute myeloid leukemia through PDX models and mitochondrial targeting.

Journal: Blood advances

Published: August 06, 2025

Sensitivity of Pediatric Myelodysplastic Syndromes With Excess of Blasts With UBTF -TD to Venetoclax/Azacitidine.

Sensitivity of Pediatric Myelodysplastic Syndromes With Excess of Blasts With UBTF -TD to Venetoclax/Azacitidine.

Journal: American journal of hematology

Published: July 13, 2025

Results in pediatric T-ALL patients treated in trial AIEOP-BFM ALL 2009: Prognostic factors in the context of modern risk-adapted therapy.

Results in pediatric T-ALL patients treated in trial AIEOP-BFM ALL 2009: Prognostic factors in the context of modern risk-adapted therapy.

Journal: HemaSphere

Published: May 27, 2025

CD84 is a specific target for acute myeloid leukemia CAR-T cell therapy.

CD84 is a specific target for acute myeloid leukemia CAR-T cell therapy.

Journal: Nature communications

Published: April 12, 2025

Showing 1-12 of 90

Last Updated: 09/26/2026